ReviewInfectious disorders drug targets2011
Hendra and nipah infection: pathology, models and potential therapies.
Review in Infectious disorders drug targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Multi-Organ RNA Virome Profiling of Edible Rodents Reveals Potential Zoonotic Viral Exposure at the Wildlife-Livestock-Human Interface in Southwest China.Pathogens (Basel, Switzerland) · 2026Article
- Exploratory Evaluation of Peptide-Based Immunization Targeting Fusion Glycoprotein-Derived Epitopes of Nipah Virus in Murine Model.Vaccines · 2026Article
- Nipah virus: a summary for clinicians.International journal of emergency medicine · 2025Review
- Pandemic potential of the Nipah virus and public health strategies adopted during outbreaks: Lessons from Kerala, India.PLOS global public health · 2024Review
- Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Review
- Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis.Computers in biology and medicine · 2021Article
- Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells.Scientific reports · 2021Article
- Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces.PLoS pathogens · 2020Article
- Review
- Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review.The veterinary quarterly · 2019Review
- Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species.Virology journal · 2018Article
- Biophysical Properties and Antiviral Activities of Measles Fusion Protein Derived Peptide Conjugated with 25-Hydroxycholesterol.Molecules (Basel, Switzerland) · 2017Article
- Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes.Journal of immunological methods · 2017Article
- Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns.Advances in virus research · 2017Review
- Article
- Paramyxovirus activation and inhibition of innate immune responses.Journal of molecular biology · 2013Review
- Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.Journal of virology · 2013Article
- Measles virus fusion machinery activated by sialic acid binding globular domain.Journal of virology · 2013Article
- A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.Peptides · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Paramyxoviridae family comprises of several genera that contain emerging or re-emerging threats for human and animal health with no real specific effective treatment available. Hendra and Nipah virus are members of a newly identified genus of emerging paramyxoviruses, Henipavirus. Since their discovery in the 1990s, henipaviruses outbreaks have been associated with high economic and public health threat potential. When compared to other paramyxoviruses, henipaviruses appear to have unique characteristics. Henipaviruses are zoonotic paramyxoviruses with a broader tropism than most other paramyxoviruses, and can cause severe acute encephalitis with unique features among viral encephalitides. There are currently no approved effective prophylactic or therapeutic treatments for henipavirus infections. Although ribavirin was empirically used and seemed beneficial during the biggest outbreak caused by one of these viruses, the Nipah virus, its efficacy is disputed in light of its lack of efficacy in several animal models of henipavirus infection. Nevertheless, because of its highly pathogenic nature, much effort has been spent in developing anti-henipavirus therapeutics. In this review we describe the unique features of henipavirus infections and the different strategies and animal models that have been developed so far in order to identify and test potential drugs to prevent or treat henipavirus infections. Some of these components have the potential to be broad-spectrum antivirals as they target effectors of viral pathogenecity common to other viruses. We will focus on small molecules or biologics, rather than vaccine strategies, that have been developed as anti-henipaviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.